Cathepsin C: structure, function, and pharmacological targeting

Abstract

Cathepsin C is a papain-like cysteine peptidase known primarily for its involvement in the activation of serine peptidases in neutrophils and other immune cells. Its critical role in this process qualifies cathepsin C as a target for the treatment of inflammatory diseases, and its most advanced inhibitor, brensocatib (Insmed), is currently in phase 3 clinical trials for the treatment of non-cystic fibrosis bronchiectasis. Beyond neutrophils, its importance is highlighted by loss-of-function mutations that cause the recessively inherited Papillon-Lefèvre syndrome. At the molecular level, cathepsin C has several structural and functional features that set it apart from other members of the family and enable its selective targeting. It possesses dipeptidyl-peptidase activity (its other common name is dipeptidyl-peptidase I) due to the presence of an additional exclusion domain that also controls its stepwise tetramerization during maturation. In this review article, we summarize the current state of the art regarding the biochemical properties of cathepsin C, its physiological and pathological roles in neutrophils and beyond, and recent advances in the development and evaluation of cathepsin C inhibitors.

Keywords

Dipeptidyl-peptidase I / DPPI / cysteine cathepsin / bronchiectasis / brensocatib

References

[1] Tallan HH,Fruton JS.On the proteolytic enzymes of animal tissues. X. beef spleen cathepsin C.J Biol Chem1952;194:793-805.

[2] Rawlings ND,Thomas PD,Bateman A.The MEROPS database of proteolytic enzymes, their substrates and inhibitors in 2017 and a comparison with peptidases in the PANTHER database.Nucleic Acids Res2018;46:D624-32. PMCID:PMC5753285

[3] Novinec M.Papain-like peptidases: structure, function, and evolution.Biomol Concepts2013;4:287-308

[4] Varda N.Evolutionary analysis of dipeptidyl peptidase I.Int J Mol Sci2022;23:1852 PMCID:PMC8836896

[5] Wu C,Tsueng G,Su AI.BioGPS: building your own mash-up of gene annotations and expression profiles.Nucleic Acids Res2016;44:D313-6. PMCID:PMC4702805

[6] Korkmaz B,Chapple I.Therapeutic targeting of cathepsin C: from pathophysiology to treatment.Pharmacol Ther2018;190:202-36.

[7] Chalmers JD,Rubino CM.Pharmacokinetic/pharmacodynamic evaluation of the dipeptidyl peptidase 1 inhibitor brensocatib for non-cystic fibrosis bronchiectasis.Clin Pharmacokinet2022;61:1457-69 PMCID:PMC9553789

[8] Nakano A,Nakano H.Papillon-Lefèvre syndrome: mutations and polymorphisms in the cathepsin C gene.J Invest Dermatol2001;116:339-43

[9] Hart TC,Bowden DW.Mutations of the cathepsin C gene are responsible for Papillon-Lefèvre syndrome.J Med Genet1999;36:881-7.

[10] Hart TC,Michalec MD.Haim-munk syndrome and papillon-Lefèvre syndrome are allelic mutations in cathepsin C.J Med Genet2000;37:88-94. PMCID:PMC1734521

[11] Sreeramulu B,Ajay P.Papillon-Lefèvre syndrome: clinical presentation and management options.Clin Cosmet Investig Dent2015;7:75-81. PMCID:PMC4507741

[12] Turk V,Vasiljeva O.Cysteine cathepsins: from structure, function and regulation to new frontiers.Biochim Biophys Acta2012;1824:68-88 PMCID:PMC7105208

[13] Turk D,Stern I.Structure of human dipeptidyl peptidase I (cathepsin C): exclusion domain added to an endopeptidase framework creates the machine for activation of granular serine proteases.EMBO J2001;20:6570-82 PMCID:PMC125750

[14] Cigic B.Location of the binding site for chloride ion activation of cathepsin C.Eur J Biochem1999;264:944-51

[15] Lindley H.The specificity of dipeptidyl aminopeptidase I (cathepsin C) and its use in peptide sequence studies.Biochem J1972;126:683-5 PMCID:PMC1178426

[16] Wang F,Deu E.Biochemical characterization of plasmodium falciparum dipeptidyl aminopeptidase 1.Mol Biochem Parasitol2011;175:10-20. PMCID:PMC3514014

[17] de Vries LE,Groborz K.Characterization of P. falciparum dipeptidyl aminopeptidase 3 specificity identifies differences in amino acid preferences between peptide-based substrates and covalent inhibitors.FEBS J2019;286:3998-4023. PMCID:PMC6851853

[18] Poreba M,Krai P.Unnatural amino acids increase activity and specificity of synthetic substrates for human and malarial cathepsin C.Amino Acids2014;46:931-43 PMCID:PMC3962583

[19] Łęgowska M,Wojtysiak A.Development of the first internally-quenched fluorescent substrates of human cathepsin C: the application in the enzyme detection in biological samples.Arch Biochem Biophys2016;612:91-102

[20] Metrione RM.The mechanism of action of dipeptidyl aminopeptidase. Inhibition by amino acid derivatives and amines; activation by aromatic compounds.Biochemistry1975;14:5249-52

[21] Mcdonald JK,Zeitman BB.Inactivation and degradation of glucagon by dipeptidyl aminopeptidase I (Cathepsin C) of rat liver.J Biol Chem1969;244:6199-208

[22] Dolenc I,Pungercic G,Turk V.Oligomeric structure and substrate induced inhibition of human cathepsin C.J Biol Chem1995;270:21626-31.

[23] Gorter J.Cathepsin C: an allosteric enzyme.Biochim Biophys Acta1970;198:546-55

[24] Nilsson KK.Polymerization reactions catalyzed by intracellular proteinases. iv. factors influencing the polymerization of dipeptide amides by cathepsin C.Biochemistry1964;3:1220-4

[25] Gittel C.Directed N-terminal elongation of unprotected peptides catalyzed by cathepsin c in water.Bioconjug Chem1995;6:70-6

[26] Tavano OL.Protein hydrolysis using proteases: an important tool for food biotechnology.J Mol Catal B-Enzym2013;90:1-11.

[27] Cigić B,Pain RH.The residual pro-part of cathepsin C fulfills the criteria required for an intramolecular chaperone in folding and stabilizing the human proenzyme.Biochemistry2000;39:12382-90

[28] Dahl SW,Lauritzen C.Human recombinant pro-dipeptidyl peptidase I (cathepsin C) can be activated by cathepsins L and S but not by autocatalytic processing.Biochemistry2001;40:1671-8

[29] Lamort AS,Czaplewski C.Processing and maturation of cathepsin C zymogen: a biochemical and molecular modeling analysis.Int J Mol Sci2019;20:4747 PMCID:PMC6801622

[30] Santilman V,Mainferme F.Importance of the propeptide in the biosynthetic maturation of rat cathepsin C.Eur J Cell Biol2002;81:654-63

[31] Rebernik M,Klemenčič M.Interplay between tetrameric structure, enzymatic activity and allosteric regulation of human dipeptidyl-peptidase I.Arch Biochem Biophys2019;675:108121

[32] Lauritzen C,Madsen MT,Martensen PM.Active recombinant rat dipeptidyl aminopeptidase I (cathepsin C) produced using the baculovirus expression system.Protein Expr Purif1998;14:434-42.

[33] Burge V,Wattiaux R.Transient membrane association of the precursors of cathepsin C during their transfer into lysosomes.Biochem J1991;275:797-800 PMCID:PMC1150125

[34] Muno D,Ueno T.Processing and transport of the precursor of cathepsin C during its transfer into lysosomes.Arch Biochem Biophys1993;306:103-10

[35] Clair J, Shi GP, Sutherland RE, Chapman HA, Caughey GH, Wolters PJ. Cathepsins L and S are not required for activation of dipeptidyl peptidase I (cathepsin C) in mice.Biol Chem2006;387:1143-6 PMCID:PMC2271110

[36] Hamon Y,Hervé V.Neutrophilic cathepsin C is maturated by a multistep proteolytic process and secreted by activated cells during inflammatory lung diseases.J Biol Chem2016;291:8486-99 PMCID:PMC4861422

[37] Olsen JG,Lauritzen C,Larsen S.Tetrameric dipeptidyl peptidase I directs substrate specificity by use of the residual pro-part domain.FEBS Lett2001;506:201-6

[38] Cigić B.Competitive inhibition of cathepsin C by guanidinium ions and reexamination of substrate inhibition.Biochem Biophys Res Commun1999;258:6-10.

[39] Rebernik M,Novinec M.The catalytic domain of cathepsin C (dipeptidyl-peptidase I) alone is a fully functional endoprotease.Protein Expr Purif2019;157:21-7

[40] Wolters PJ,Caughey GH.Dipeptidyl peptidase I cleaves matrix-associated proteins and is expressed mainly by mast cells in normal dog airways.Am J Respir Cell Mol Biol2000;22:183-90

[41] Kuribayashi M,Ohmori T,Imoto T.Endopeptidase activity of cathepsin C, dipeptidyl aminopeptidase I, from bovine spleen.J Biochem1993;113:441-9

[42] Pham CT.Neutrophil serine proteases: specific regulators of inflammation.Nat Rev Immunol2006;6:541-50

[43] Perera NC,Kittel H,Kremmer E.NSP4, an elastase-related protease in human neutrophils with arginine specificity.Proc Natl Acad Sci U S A2012;109:6229-34 PMCID:PMC3341072

[44] Salvesen G.An unusual specificity in the activation of neutrophil serine proteinase zymogens.Biochemistry1990;29:5304-8

[45] Wolters PJ,Muilenburg DJ,Caughey GH.Dipeptidyl peptidase I is essential for activation of mast cell chymases, but not tryptases, in mice.J Biol Chem2001;276:18551-6

[46] Pham CT.Dipeptidyl peptidase I is required for the processing and activation of granzymes A and B in vivo.Proc Natl Acad Sci U S A1999;96:8627-32 PMCID:PMC17567

[47] Freer ST,Robertus JD,Xuong NH.Chymotrypsinogen: 2.5-angstrom crystal structure, comparison with alpha-chymotrypsin, and implications for zymogen activation.Biochemistry1970;9:1997-2009

[48] Reiling KK,Miercke LJ,Caughey GH.Structure of human pro-chymase: a model for the activating transition of granule-associated proteases.Biochemistry2003;42:2616-24

[49] Gullberg U,Garwicz D,Olsson I.Biosynthesis, processing and sorting of neutrophil proteins: insight into neutrophil granule development.Eur J Haematol1997;58:137-53

[50] Garwicz D,Persson A.On the role of the proform-conformation for processing and intracellular sorting of human cathepsin G.Blood1998;92:1415-22

[51] Garwicz D,Jacobsen SE,Lindmark A.Biosynthetic profiles of neutrophil serine proteases in a human bone marrow-derived cellular myeloid differentiation model.Haematologica2005;90:38-44.

[52] Brinkmann V,Goosmann C.Neutrophil extracellular traps kill bacteria.Science2004;303:1532-5

[53] Korkmaz B,Jenne DE.Neutrophil elastase, proteinase 3, and cathepsin G as therapeutic targets in human diseases.Pharmacol Rev2010;62:726-59. PMCID:PMC2993259

[54] Ruffell B,Cottone L.Cathepsin C is a tissue-specific regulator of squamous carcinogenesis.Genes Dev2013;27:2086-98 PMCID:PMC3850093

[55] Wolters PJ,Blount JL.Regulated expression, processing, and secretion of dog mast cell dipeptidyl peptidase I.J Biol Chem1998;273:15514-20

[56] Dikov MM,Yeola S.Processing of procarboxypeptidase A and other zymogens in murine mast cells.J Biol Chem1994;269:25897-904.

[57] Gullberg U,Nilsson E,Olsson I.Processing of human cathepsin G after transfection to the rat basophilic/mast cell tumor line RBL.J Biol Chem1994;269:25219-25

[58] McEuen AR,Walls AF.The conversion of recombinant human mast cell prochymase to enzymatically active chymase by dipeptidyl peptidase I is inhibited by heparin and histamine.Eur J Biochem1998;253:300-8

[59] Le QT,Xia HZ,Katunuma N.Promiscuous processing of human alphabeta-protryptases by cathepsins L, B, and C.J Immunol2011;186:7136-43 PMCID:PMC3339195

[60] Le QT,Zhao W.Processing of human protryptase in mast cells involves cathepsins L, B, and C.J Immunol2011;187:1912-8 PMCID:PMC3150348

[61] Clair J, Pham CT, Villalta SA, Caughey GH, Wolters PJ. Mast cell dipeptidyl peptidase I mediates survival from sepsis.J Clin Invest2004;113:628-34. PMCID:PMC338261

[62] Jenne D,Haefliger JA,Groscurth P.Identification and sequencing of cDNA clones encoding the granule-associated serine proteases granzymes D, E, and F of cytolytic T lymphocytes.Proc Natl Acad Sci U S A1988;85:4814-8. PMCID:PMC280526

[63] Caputo A,Winkler U,Bleackley R.Activation of recombinant murine cytotoxic cell proteinase-1 requires deletion of an amino-terminal dipeptide.J Biol Chem1993;268:17672-5

[64] Brown GR,Thiele DL.Dipeptidyl peptidase I is enriched in granules of in vitro- and in vivo-activated cytotoxic T lymphocytes.J Immunol1993;150:4733-42.

[65] Mcguire M,Thiele D.Generation of active myeloid and lymphoid granule serine proteases requires processing by the granule thiol protease dipeptidyl peptidase I.J Biol Chem1993;268:2458-67

[66] Grossman WJ,Tollefsen BL,Atkinson JP.Differential expression of granzymes A and B in human cytotoxic lymphocyte subsets and T regulatory cells.Blood2004;104:2840-8

[67] Pham CT,Mercer JD.Production of fully active recombinant murine granzyme B in yeast.J Biol Chem1998;273:1629-33.

[68] Alam S,Liu S.Up-regulated cathepsin C induces macrophage M1 polarization through FAK-triggered p38 MAPK/NF-κB pathway.Exp Cell Res2019;382:111472

[69] Dai J,Zhang Q.Cathepsin C is involved in macrophage M1 polarization via p38/MAPK pathway in sudden cardiac death.Cardiovasc Ther2021;2021:6139732 PMCID:PMC8536465

[70] Liu Q,Liu S.Cathepsin C promotes microglia M1 polarization and aggravates neuroinflammation via activation of Ca²⁺-dependent PKC/p38MAPK/NF-κB pathway.J Neuroinflamm2019;16:1-18

[71] Adkison AM,Pham CTN.Dipeptidyl peptidase I activates neutrophil-derived serine proteases and regulates the development of acute experimental arthritis find the latest version: dipeptidyl peptidase I activates neutrophil-derived serine proteases and regulates the development.J Clin Invest2002;109:363-71

[72] Chu Y,Walls AF.The regulatory role of dipeptidyl peptidase I on the activation of immune granulocytes.Cell Biol Int2017;41:1093-102.

[73] Pagano MB,Ennis TL.Critical role of dipeptidyl peptidase I in neutrophil recruitment during the development of experimental abdominal aortic aneurysms.Proc Natl Acad Sci U S A2007;104:2855-60 PMCID:PMC1797622

[74] John DS,Krüger B.Deficiency of cathepsin C ameliorates severity of acute pancreatitis by reduction of neutrophil elastase activation and cleavage of E-cadherin.J Biol Chem2019;294:697-707 PMCID:PMC6333881

[75] Fan K,Fan B.Up-regulation of microglial cathepsin C expression and activity in lipopolysaccharide-induced neuroinflammation.J Neuroinflamm2012;9:1-13

[76] Keir HR,Dicker AJ.Neutrophil extracellular traps, disease severity, and antibiotic response in bronchiectasis: an international, observational, multicohort study.Lancet Respir Med2021;9:873-84

[77] Kim S.Role of neutrophils in mucus hypersecretion in COPD and implications for therapy.Treat Respir Med2004;3:147-59

[78] Guarino C,Croix C.Prolonged pharmacological inhibition of cathepsin C results in elimination of neutrophil serine proteases.Biochem Pharmacol2017;131:52-67

[79] Sanchez Klose FP,Dahlstrand Rudin A.A rare CTSC mutation in Papillon-Lefèvre syndrome results in abolished serine protease activity and reduced NET formation but otherwise normal neutrophil function.PLoS One2021;16:e0261724 PMCID:PMC8691626

[80] Bullón P,Román-Malo L.Autophagic dysfunction in patients with Papillon-Lefèvre syndrome is restored by recombinant cathepsin C treatment.J Allergy Clin Immunol2018;142:1131-1143.e7

[81] Suban D,Renko M,Turk V.Cathepsin C and plasma glutamate carboxypeptidase secreted from Fischer rat thyroid cells liberate thyroxin from the N-terminus of thyroglobulin.Biochimie2012;94:719-26

[82] Bernardini F.Lysosomal degradation of cholecystokinin-(29-33)-amide in mouse brain is dependent on tripeptidyl peptidase-I: implications for the degradation and storage of peptides in classical late-infantile neuronal ceroid lipofuscinosis.Biochem J2002;366:521-9 PMCID:PMC1222804

[83] Sleat DE,Lackland H.Association of mutations in a lysosomal protein with classical late-infantile neuronal ceroid lipofuscinosis.Science1997;277:1802-5

[84] Kim KH,Sleat DE.Dipeptidyl-peptidase I does not functionally compensate for the loss of tripeptidyl-peptidase I in the neurodegenerative disease late-infantile neuronal ceroid lipofuscinosis.Biochem J2008;415:225-32 PMCID:PMC4353488

[85] Zhang GP,Li SQ.Cathepsin C interacts with TNF-α/p38 MAPK signaling pathway to promote proliferation and metastasis in hepatocellular carcinoma.Cancer Res Treat2020;52:10-23 PMCID:PMC6962486

[86] Kim S,Kim N.Decursin inhibits cell growth and autophagic flux in gastric cancer via suppression of cathepsin C.Am J Cancer Res2021;11:1304. PMCID:PMC8085838

[87] Khaket TP,Khan I,Kang SC.Targeting of cathepsin C induces autophagic dysregulation that directs ER stress mediated cellular cytotoxicity in colorectal cancer cells.Cell Signal2018;46:92-102

[88] Xiao Y,Li J.Cathepsin C promotes breast cancer lung metastasis by modulating neutrophil infiltration and neutrophil extracellular trap formation.Cancer Cell2021;39:423-437.e7

[89] Korkmaz B,Domain R.Cathepsin C inhibition as a potential treatment strategy in cancer.Biochem Pharmacol2021;194:114803.

[90] Kavčič N,Sobotič B.Intracellular cathepsin C levels determine sensitivity of cells to leucyl-leucine methyl ester-triggered apoptosis.FEBS J2020;287:5148-66

[91] Nicklin MJ.Inhibition of cysteine proteinases and dipeptidyl peptidase I by egg-white cystatin.Biochem J1984;223:245-53 PMCID:PMC1144286

[92] Tušar L,Turk B.Mechanisms applied by protein inhibitors to inhibit cysteine proteases.Int J Mol Sci2021;22:997 PMCID:PMC7863939

[93] Hamilton G,Schuettelkopf AW.Cystatin F is a cathepsin C-directed protease inhibitor regulated by proteolysis.EMBO J2008;27:499-508 PMCID:PMC2241651

[94] Halfon S,Foster J.Leukocystatin, a new Class II cystatin expressed selectively by hematopoietic cells.J Biol Chem1998;273:16400-8.

[95] Božič J.Feedback regulation of cathepsin C by the propeptide dipeptides of granzymes A and B.ACSi2019;66:501-9

[96] Méthot N,Guay D.Inhibition of the activation of multiple serine proteases with a cathepsin C inhibitor requires sustained exposure to prevent pro-enzyme processing.J Biol Chem2007;282:20836-46

[97] Mølgaard A,Lauritzen C,Petersen G.The crystal structure of human dipeptidyl peptidase I (cathepsin C) in complex with the inhibitor Gly-Phe-CHN2.Biochem J2007;401:645-50 PMCID:PMC1770842

[98] Green GD.Peptidyl diazomethyl ketones are specific inactivators of thiol proteinases.J Biol Chem1981;256:1923-8

[99] Laine DI.Inhibitors of cathepsin C (dipeptidyl peptidase I).Expert Opin Ther Pat2010;20:497-506

[100] Furber M,Gardiner P.Cathepsin C inhibitors: property optimization and identification of a clinical candidate.J Med Chem2014;57:2357-67.

[101] Gardiner P,Clifton S,Benjamin A.Neutrophil maturation rate determines the effects of dipeptidyl peptidase 1 inhibition on neutrophil serine protease activity.Br J Pharmacol2016;173:2390-401 PMCID:PMC4945769

[102] Bragg RA,Gustafsson F.Aortic binding of AZD5248: mechanistic insight and reactivity assays to support lead optimzation.Chem Res Toxicol2015;28:1991-9

[103] Doyle K,Käck H.Discovery of second generation reversible covalent DPP1 inhibitors leading to an oxazepane amidoacetonitrile based clinical candidate (AZD7986).J Med Chem2016;59:9457-72

[104] Palmér R,Jauhiainen A.Dipeptidyl peptidase 1 inhibitor AZD7986 induces a sustained, exposure-dependent reduction in neutrophil elastase activity in healthy subjects.Clin Pharmacol Ther2018;104:1155-64 PMCID:PMC6282495

[105] Chalmers JD,Metersky ML.WILLOW InvestigatorsPhase 2 trial of the DPP-1 inhibitor brensocatib in bronchiectasis.N Engl J Med2020;383:2127-37

[106] Sinha S,Arora R.Dexamethasone modulates immature neutrophils and interferon programming in severe COVID-19.Nat Med2022;28:201-11. PMCID:PMC8799469

[107] Seren S,Keleş I.Proteinase release from activated neutrophils in mechanically ventilated patients with non-COVID-19 and COVID-19 pneumonia.Eur Respir J2021;57:2003755 PMCID:PMC8082325

[108] Keir HR,Abo-Leyah H.STOP-COVID19 InvestigatorsDipeptidyl peptidase-1 inhibition in patients hospitalised with COVID-19: a multicentre, double-blind, randomised, parallel-group, placebo-controlled trial.Lancet Respir Med2022;10:1119-28 PMCID:PMC9442496

[109] Korkmaz B,Wysocka M.Structure-based design and in vivo anti-arthritic activity evaluation of a potent dipeptidyl cyclopropyl nitrile inhibitor of cathepsin C.Biochem Pharmacol2019;164:349-67

[110] Rehm SRT,Morrone C.Premedication with a cathepsin C inhibitor alleviates early primary graft dysfunction in mouse recipients after lung transplantation.Sci Rep2019;9:9925 PMCID:PMC6616352

[111] Miller BE,Goyal N.Epithelial desquamation observed in a phase I study of an oral cathepsin C inhibitor (GSK2793660).Br J Clin Pharmacol2017;83:2813-20 PMCID:PMC5698569

[112] Badorrek P,Kögler H.Phase I characterization of the novel cathepsin C inhibitor BI 1291583.Am J Resp Crit Care2022;205:A4777

[113] Pettersen EF,Huang CC.UCSF Chimera-a visualization system for exploratory research and analysis.J Comput Chem2004;25:1605-12

[114] Shen XB,Zhang ZY,Liu XH.Cathepsin C inhibitors as anti-inflammatory drug discovery: challenges and opportunities.Eur J Med Chem2021;225:113818

[115] Chen X,Zhang Z.Discovery and in vivo anti-inflammatory activity evaluation of a novel non-peptidyl non-covalent cathepsin C inhibitor.J Med Chem2021;64:11857-85

[116] Chen X,Du J.Non-peptidyl non-covalent cathepsin C inhibitoEEr bearing a unique thiophene-substituted pyridine: design, structure-activity relationship and anti-inflammatory activity in vivo.Eur J Med Chem2022;236:114368

[117] Radzey H,Klimpel D,Sommerhoff CP.E-64c-hydrazide: a lead structure for the development of irreversible cathepsin C inhibitors.ChemMedChem2013;8:1314-21

[118] Zhang R,Windsor WT.Azapeptides as inhibitors of the hepatitis C virus NS3 serine protease.Bioorg Med Chem Lett2002;12:1005-8

[119] Venkatraman S,Nimkar S,Aubé J.Design, synthesis, and evaluation of azapeptides as substrates and inhibitors for human rhinovirus 3C protease.Bioorg Med Chem Lett1999;9:577-80

[120] Verhelst SH,Arastu-Kapur S,Bogyo M.Novel aza peptide inhibitors and active-site probes of papain-family cysteine proteases.Chembiochem2006;7:943-50

[121] Bondebjerg J,Valeur KR.Novel semicarbazide-derived inhibitors of human dipeptidyl peptidase I (hDPPI).Bioorg Med Chem2005;13:4408-24

[122] Drąg M,Pawełczak M,Grzonka Z.Toward very potent, non-covalent organophosphonate inhibitors of cathepsin C and related enzymes by 2-amino-1-hydroxy-alkanephosphonates dipeptides.Biochimie2013;95:1640-9

[123] Jewgiński MP,Pawełczak M.Synthesis of hybrid tripeptide peptidomimetics containing dehydroamino acid and aminophosphonic acid in the chain and evaluation of their activity toward cathepsin C.Chem Biodivers2022;19:e202101019

[124] Sun H,Hou W.Focusing on probe-modified peptides: a quick and effective method for target identification.Chem Commun2016;52:10225-8

[125] Hou W,Ma Y,Zhang Z.Identification and optimization of novel cathepsin C inhibitors derived from EGFR inhibitors.J Med Chem2019;62:5901-19.

[126] Wang J,Zhou X.Inhibitory effect of triperygium wilfordii polyglucoside on dipeptidyl peptidase I in vivo and in vitro.Biomed Pharmacother2017;96:466-70.

[127] Ulčakar L.Inhibition of human cathepsins B and L by caffeic acid and its derivatives.Biomolecules2020;11:31 PMCID:PMC7824550

[128] Touaibia M,Doiron J.Caffeic acid, a versatile pharmacophore: an overview.Mini Rev Med Chem2011;11:695-713

[129] Novinec M,Baici A.Probing the activity modification space of the cysteine peptidase cathepsin K with novel allosteric modifiers.PLoS One2014;9:e106642 PMCID:PMC4153677

[130] Changeux JP.Allosteric modulation as a unifying mechanism for receptor function and regulation.Cell2016;166:1084-102

[131] Novinec M,Caflisch A,Lenarčič B.A novel allosteric mechanism in the cysteine peptidase cathepsin K discovered by computational methods.Nat Commun2014;5:3287

[132] Panwar P,Guido RV,Delaisse JM.A novel approach to inhibit bone resorption: exosite inhibitors against cathepsin K.Br J Pharmacol2016;173:396-410 PMCID:PMC5341232

[133] Sanchez MI,Lehmann C.Identification of plasmodium dipeptidyl aminopeptidase allosteric inhibitors by high throughput screening.PLoS One2019;14:e0226270 PMCID:PMC6919601

[134] McClung MR,Papapoulos SE.LOFT InvestigatorsOdanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT extension study.Lancet Diabetes Endo2019;7:899-911